NIBSC Confidence in Biological Medicines

WHO Reference Reagent Islet Cell Antibodies NIBSC code: 97/550 Instructions for use (Version 4.0, Dated 28/03/2013)

1. INTENDED USE

The First WHO Reference Reagent for Islet Cell Antibodies was established at the 50th meeting of the Expert Committee on Biological Standardisation, October 1999.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

20 uniits of islet cell antibodies per ampoule 100 units of anti-GAD65 per ampoule 100 units of anti-IA-2 per ampoule

4. CONTENTS

Country of origin of biological material: United Kingdom.

Each ampoule contains the freeze-dried residue of 0.4ml of solution which contained: 0.4mg Trehalose

0.4mg Trenaiose 0.1ml serum

5. STORAGE

Unopened ampoules should be stored at -20°C

Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

The standard should be reconstituted with 0.4ml of sterile distilled water and used within a few hours. Any remaining material should be stored at either -20°C or -70°C.

The material should not be frozen and thawed more than once.

8. STABILITY

It is the policy of WHO not to assign an expiry date to their international reference materials. They remain valid with the assigned potency and status until withdrawn or amended.

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

In addition, once reconstituted, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use.

NIBSC follows the policy of WHO with respect to its reference materials.

Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

9. REFERENCES

Mire-Sluis, A.R, Gaines Das, R. Lernmark, A. The World Health Organisation International Collaborative Study for islet cell antibodies. Diabetologia, Volume 43, Issue 10, October 2000, Pages 1282-1292.

10. FURTHER INFORMATION

Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/
Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx
Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx
NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

11. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

12. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

13. MATERIAL SAFETY SHEET





NIBSC Confidence in Biological Medicines

(Add or amend as

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classifiednecessary)

(EC) No 12/2/2008: Not applicable or not classified necessary)					
Physical and Chemical properties					
Physical appearance		nce:	Corrosive:	No	
Freeze-dried powder					
Stable:	Yes		Oxidising:	No	
Hygroscopic:	Yes		Irritant:	No	
Flammable:	No		Handling:See	caution, Section 2	
Other (specify):	ther (specify): Contains material of human origin				
Toxicological properties					
Effects of inhalation:		Not established, avoid inhalation			
Effects of ingestion:		Not established, avoid ingestion			
Effects of skin absorption:		Not established, avoid contact with skin			
Suggested First Aid					
Inhalation:	Seek r	Seek medical advice			
Ingestion:	Seek medical advice				
Contact with eyes:	Wash	Vash with copious amounts of water. Seek			
medical advice					
Contact with skin:	Wash thoroughly with water.				
Action on Spillage and Method of Disposal					
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an					

olefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.

14. LIABILITY AND LOSS

biological waste.

appropriate disinfectant followed by water.

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Absorbent materials used to treat spillage should be treated as

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

15. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

Net weight: 1 mg

Toxicity Statement: Non-toxic

Veterinary certificate or other statement if applicable.

Attached: No

17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_bi

National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

